Table 1.
The Clinical Characteristics of Patients in Both Groups
| Characteristics | Group A (n=248) | Group B (n=71) | P |
|---|---|---|---|
| Age (years) | 0.077C | ||
| <40 | 205 (82.7%) | 52 (73.2%) | |
| >40 | 43 (17.3%) | 19 (26.8%) | |
| BMI (kg/m2)† | 20.69 [18.97,22.81] | 21.26 [19.90,23.80] | 0.015M |
| Gravidity† | 2 [1,3] | 3 [1,4] | 0.313M |
| Parity† | 0 [0,1] | 1 [0,1] | 0.101M |
| Antecedent pregnancy | 0.002F | ||
| Mole | 212 (85.5%) | 64 (90.1%) | |
| Abortion | 35 (14.1%) | 3 (4.2%) | |
| Live Birth | 1 (0.4%) | 4 (5.6%) | |
| Interval between antecedent pregnancy and first-line MTX initiation, months | 0.623F | ||
| <4 | 214 (86.3%) | 66 (93.0%) | |
| 4–6 | 25 (10.1%) | 4 (5.6%) | |
| 7–12 | 2 (0.8%) | 0 (0.0%) | |
| >13 | 7 (2.8%) | 1 (1.4%) | |
| Serum hCG at MTX initiation, IU/L | 0.140F | ||
| <1,000 | 82 (33.1%) | 15 (21.1%) | |
| 1,000–10,000 | 97 (39.1%) | 37 (52.1%) | |
| 10,000–100,000 | 66 (26.6%) | 19 (26.8%) | |
| ≥100,000 | 3 (1.2%) | 0 (0.0%) | |
| FIGO score† | 2 [1,3] | 2 [1,3] | 0.683M |
| GTN stage | 0.404F | ||
| I | 82 (33.1%) | 29 (40.8%) | |
| II | 2 (0.8%) | 0 (0.0%) | |
| III | 164 (66.1%) | 42 (59.2%) | |
| Pretreatment β-hCG (IU/L)† | 3,019 [615,10,961] | 3,922 [1,386,14,532] | 0.197M |
| Pretreatment WBC (x109/L)† | 6.2 [5.3,7.4] | 6.0 [4.9,7.0] | 0.206M |
| Pretreatment Neutrophil (x109/L)† | 3.8 [3.2,5.0] | 3.8 [3.1,5.0] | 0.673M |
| Pretreatment RBC (x1012/L)† | 3.98 [3.67,4.22] | 4.09 [3.50,4.29] | 0.380M |
| Pretreatment Hb (g/L)† | 121 [112,129] | 117 [106,130] | 0.342M |
| Pretreatment PLT (x109/L)† | 202 [181,244] | 205 [188,240] | 0.491M |
| Pretreatment TP (g/L) ¶¶ | 70.2 ± 6.5 | 69.1 ± 6.2 | 0.208S |
| Pretreatment ALB (g/L)† | 44.9 [42.3,47.3] | 43.6 [41.5,45.7] | 0.001M |
| Pretreatment GLO† | 25.8 [23.3,28.4] | 25.9 [23.2,28.2] | 0.965M |
| ALB/GLO† | 1.72 [1.58,1.93] | 1.67 [1.49,1.88] | 0.133M |
| Pretreatment AST (U/L) † | 16 [10,27] | 16 [11,24] | 0.581M |
| Pretreatment ALT (U/L) † | 18 [15,24] | 17 [15,21] | 0.149M |
| Pretreatment TBIL (µmol/L) † | 9.90 [7.60,12.80] | 9.30 [7.30,13.00] | 0.586M |
| Pretreatment DBIL (µmol/L) † | 3.3 [2.4,4.6] | 3.1 [2.5,4.0] | 0.476M |
| Pretreatment IBIL (µmol/L)† | 6.9 [4.7,8.9] | 6.7 [4.6,9.5] | 0.910M |
| Pretreatment LDH (U/L)† | 159 [137,184] | 156 [143,180] | 0.838M |
| Pretreatment BUN (mmol/L)† | 3.76 [3.01,4.50] | 4.06 [3.24,4.67] | 0.202M |
| Pretreatment Scr (µmol/L)† | 67.9 [62.0,71.7] | 70.7 [66.0,77.8] | 0.001M |
| BUN/Scr† | 0.054 [0.046,0.068] | 0.058 [0.045,0.070] | 0.813M |
| Pretreatment Ccr (mL/min)† | 89.4 [78.3,102.4] | 86.1 [75.4,99.8] | 0.108M |
| Pretreatment GFR (mL/min)† | 104.1 [95.7,116.7] | 97.2 [88.5,106.5] | <0.001M |
Notes: †Median and interquartile range. ¶¶Mean and standard deviation. C, Chi-square test; F, Fisher’s exact test; M, Mann–Whitney U-test; S, Student’s t-test.
Abbreviations: BMI, body mass index; MTX, methotrexate; hCG, human chorionic gonadotropin; FIGO, Federation of Gynecology and Obstetrics; GTN, gestational trophoblastic neoplasia; WBC, white blood cell; RBC, red blood cell; HB, hemoglobin; PLT, platelet; TP, total protein; ALB, albumin; GLO, globulin; AST, aspartate aminotransferase; ALT, alanine aminotransferase; TBIL, total bilirubin; DBIL, direct bilirubin; IBIL, indirect bilirubin; LDH, lactate dehydrogenase; BUN, blood urea nitrogen; Scr, serum creatinine; Ccr, creatinine clearance rate; GFR, glomerular filtration rate.